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Skin ﬁbroblastsNuclear envelope-related muscular dystrophies, in particular those referred to as laminopathies, are relatively
novel and unclear diseases, also considering the increasing number of mutations identiﬁed so far in genes of
the nuclear envelope. As regard LMNA gene, only tentative relations between phenotype, type and localization
of themutations have been established in striatedmuscle diseases, while laminopathies affecting adipose tissue,
peripheral nerves or progerioid syndromes could be linked to speciﬁc genetic variants. This study describes the
biochemical phenotype of neuromuscular laminopathies in samples derived from LMNAmutant patients. Since it
has been reported that nuclear alterations, due to LMNA defects, are present also inﬁbroblasts fromEmery–Dreifuss
muscular dystrophy and familial partial lipodystrophy patients, we analyzed 2D-maps of skin ﬁbroblasts of pa-
tients carrying 12 different LMNAmutations spread along the entire gene. To recognize distinctive proteins un-
derlying affected biochemical pathways, we compared them with ﬁbroblasts from healthy controls and, more
importantly, ﬁbroblasts from patients with non-lamin related neuromuscular disorders. We found less abun-
dance of cytoskeletal/structural proteins, conﬁrming a dominant role for Lamin A/C in structural support of nu-
clear architecture. Interestingly, we also established signiﬁcant changes in the expression of proteins involved in
cellular energy production and oxidative stress response. To our knowledge, this is the ﬁrst report where proteo-
mics was applied to characterize ex-vivo cells from LMNA patients, suggesting that this may represent a new ap-
proach to better understand the molecular mechanisms of these rare diseases and facilitate the development of
novel therapeutic treatments.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Alterations in the LMNA gene, encoding the nuclear envelope pro-
teins Lamin A/C, lead to a heterogeneous spectrum of human diseases
collectively denominated laminopathies, which can be classiﬁed into
tissue-restricted or systemic disorders. The former includes Emery–
Dreifuss and limb-girdle muscular dystrophies [1,2], Charcot–Marie–
Tooth neuropathy [3], dilated cardiomyopathy and conduction sys-
tem defects [4], and Dunningan-type familial partial lipodystrophy
[5]. The second group comprises developmental abnormalities with+39 02 26436585.
o).
l rights reserved.or without premature aging (mandibuloacral dysplasia, Hutchinson–
Gilford and atypical Werner progeria syndromes, restrictive dermo-
pathy [6–8]). Although some genotype–phenotype correlation has
been attempted [9], these disorders display a striking intra-familiar and
inter-familiar clinical heterogeneity, which may be partly ascribable to
different genetic backgrounds.
However, in spite of more than 400 LMNA mutations described to
date, the understanding of pathogenetic mechanisms involved in the
different clinical forms of laminopathies remains incomplete, espe-
cially for neuromuscular subtypes. Several hypotheses have been pro-
posed so far, reﬂecting the variety of cellular functions involving
Lamin A/C. Firstly, Lamin A/C as type V nuclear intermediate ﬁlament
proteins, is involved in the structural support of nuclear architecture.
LMNA mutations may therefore increase nuclear fragility, disrupting
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and consequently leading to a greater susceptibility to physical stress,
especially in tissues exposed to mechanical strain such as skeletal and
cardiac muscle [10,11]. Lamin A/C defects can also affect different nu-
clear functions such as DNA replication, RNA transcription and matu-
ration [12] by interacting with chromatin and with several
transcription factors [13]. In addition, Lamin A/C is also involved in
a variety of signaling pathways affecting cell growth and differentia-
tion, including MAPK, TGFβ, Notch, pRb and MyoD [14–17]. It has
been recently suggested that muscle atrophy may also depend on de-
fects in the neuromuscular junction secondary to synaptic nuclei mis-
positioning [18]. Finally, it is now believed that LMNA mutations
primarily affect not only myoﬁbers but also the efﬁciency of satellite
cells in muscle repair and regeneration [19].
Many studies have demonstrated that Lamin A/C defects induce
changes in nuclear morphology in a subset of cells, like misshapen
nuclei, nuclear pores clustering, mislocalization of associated proteins
and aberrant intranuclear lamin foci [20]. However, the relevance of
these abnormalities and their possible pathogenetic mechanism is
still unclear, since no obvious links have been established with the
heterogeneous clinical phenotypes.
Proteomic studies have been increasingly used to obtain a com-
prehensive and unbiased characterization of human disorders be-
cause of their capability to detect both qualitative and quantitative
gene expression differences [21]. This kind of approach gives the op-
portunity to explore the entire proteome, revealing alterations in un-
expected signaling pathways. For example, a recent proteomic
proﬁling of heart in a mouse model of Duchenne muscular dystrophy
identiﬁed 29 differentially expressed proteins mainly involved in en-
ergy metabolism and contractile machinery, previously not correlated
to the disease [22].
Our approach aimed at describing the biochemical phenotype of
neuromuscular laminopathies, in order to improve our knowledge
on the molecular pathways involved in Lamin A/C diseases. Skin ﬁ-
broblasts from LMNAmutation carriers with personal or family histo-
ry of skeletal or cardiac muscle disorder were subjected to proteomic
analysis to identify differentially expressed proteins compared to
controls. Gene Ontology and Principal Component Analysis (PCA)
with Western Blot (WB) validation suggested that LMNA defects af-
fect primarily the expression of proteins involved in cytoskeleton or-
ganization, energy metabolism and oxidative stress response, even
when compared to other neuromuscular diseases. To our knowledge,
this is the ﬁrst study where a combination of proteomics procedures
was applied to characterize LMNA patient samples.
2. Materials and methods
2.1. Materials
Trypsin-EDTA, minimum Eagle's medium and fetal calf serum
were purchased from Gibco, Invitrogen (Carlsbad, CA, USA). Dimethyl
sulfoxide, PBS, bovine serum albumin (BSA), urea, thiourea, protease
inhibitors, trizma base, glycine, CHAPS, 1,4-dithioerythritol (DTE),
iodoacetamide, alpha-cyano-4-hydroxycinnamic acid, mouse mono-
clonal Alpha-Tubulin (used at 1:1000 v/v dilution) and Actin anti-
body (used at 1:5000 v/v dilution) were from SIGMA Chemical
Company (St. Louis, MO, USA). Phosphatase inhibitors were from Cal-
Biochem (San Diego, CA, USA). Zwittergent, Destreak, IPG buffer,
Immobiline dry strips pH 3-10NL 13 cm, mineral oil, Hybond-ECL ni-
trocellulose membrane, ECL detection kit and appropriate HRP-
conjugated secondary antibodies were from GE Healthcare (Uppsala,
Sweden). Acrylamide 30% solution and Colloidal Brilliant Blue Coomas-
sie were from BioRad Laboratories (Hercules, CA, USA). Trypsin se-
quencing grade was from Roche Diagnostics (Mannheim, Germany).
Goat polyclonal Lamin A/C (N-18) antibody (used at 1:1000 v/v dilu-
tion) was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbitpolyclonal Alpha B Crystallin antibody (used at 1:200 v/v dilution) was
from Covance (Princeton, NJ, USA). Goat polyclonal Triosephosphate
Isomerase antibody (used at 1:5000 v/v dilution) was from Abcam
Ltd. (Cambridge, UK).
2.2. Methods
2.2.1. Clinical evaluation
Ethics approval for this studywas obtained by the San Raffaele Insti-
tute Ethics Committee (protocol LMNA-02). The investigation con-
formed with the principles outlined in the Declaration of Helsinki.
Patients underwent complete neurological and cardiological examina-
tion. Neurological assessment included evaluation of muscle weakness,
presence of contractures, functional disability, progression of disease,
electromyography and determination of serum creatine kinase levels.
Cardiological assessment included 12-leads electrocardiogram, echo-
cardiogram, 24 hour-Holter monitoring, heart magnetic resonance im-
aging with injection of paramagnetic contrast medium and, in the
absence of serious neurological impairment, ergometric test.
2.2.2. Genetic analysis
Written informed consent was obtained before genetic analysis.
Genomic DNA extraction, PCR ampliﬁcation, denaturing high pressure
liquid chromatography and direct sequencing of LMNA gene were
performed as previously described [23]. Primer sequences and reac-
tion conditions are available upon request. LMNA reference sequences
were NCBI NG_008692.1 for genomic DNA, NCBI NM_170707 for
lamin A cDNA and NCBI NM_005572 for lamin C cDNA. Nucleotides
were numbered starting from ATG.
2.2.3. Skin biopsies and ﬁbroblast culture
A skin specimen of approximately 2 mm3 was taken by exci-
sion under local anesthesia from an avascular area of the anterior
aspect of forearm of 30 patients and 3 healthy controls. Fibro-
blasts were split with trypsin-EDTA 0.25% and progressively ex-
panded in 60 mm culture dishes in minimum Eagle's medium
(MEM) supplemented with 10% fetal calf serum. At the fourth pas-
sage in culture, 2–3*10
6
ﬁbroblasts were harvested, resuspended in
MEM supplemented with 30% fetal calf serum and 5% dimethyl sulfox-
ide (freezing medium) and frozen in liquid nitrogen in several aliquots
for future experiments. Skin ﬁbroblasts, expanded in 7 passages up to
10*10
6, were detached with trypsin-EDTA 0.25%, washed twice with
ice-cold PBS and divided in two aliquots and stored at −80 °C until
analysis.
2.2.4. Proteomic analysis
2.2.4.1. Cell lysis. Skin ﬁbroblast samples were lysed for 40 min on mix-
ing wheel at 4 °C in 400 μl of lysis buffer (5 M urea, 2 M thiourea, 2%
CHAPS w/v, 2% Zwittergent v/v, protease and phosphatase inhibitors).
The lysates were centrifuged at 14,000 rpm for 15 min at 15 °C and
stored at −80 °C. The recovered supernatant was analyzed to deter-
mine total protein concentration using BioRad protein assay and BSA
as standard.
2.2.4.2. Two-dimensional gel electrophoresis. For 2D electrophoresis,
300 μg total proteins were loaded on each gel and each sample was
run in triplicates. Prior to the ﬁrst dimension of isoelectric focusing,
each sample was added of Destreak (ﬁnal concentration: 100 mM)
and IPG buffer (ﬁnal concentration: 0.5%) and then run at
100,000 V h on 13 cm strips, with a non linear gradient pH 3–10.
The second dimension was SDS–PAGE 10%, stained with Colloidal
Brilliant Blue Coomassie, upon reduction with DTE and alkylation
with iodoacetamide of the strips. We intentionally used CBB as pro-
tein stain, because it is very cheap, really reproducible and it is
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staining [24].
2.2.4.3. Gel image analysis. Gel images were acquired by ProXPRESS 2D
Proteomic Imaging System and quantitative comparisons of spot in-
tensities were carried out using Progenesis SameSpots (Nonlinear Dy-
namics, Newcastle upon Tyne, UK). Background subtraction and spot
intensity normalization were automatically performed by Progenesis
SameSpots. Relative spot intensity values were calculated on a loga-
rithmic scale and converted to relative fold-difference levels. Statisti-
cal analysis was also automatically performed by Progenesis SameSpots
on intensity values of protein spots from three separate gels for each sam-
ple. Differential spots, characterized by a fold-change≥1.5 and p-
valueb0.05, were identiﬁed by in-gel digestion followed by MALDI-TOF
or nLC-ESI mass spectrometry analysis.
2.2.4.4. In-gel digestion and mass spectrometry analysis. The spots of
interest were manually excised from the gels, destained, sequentially
reduced and alkylated, and digested overnight with sequencing-
grade modiﬁed trypsin, as previously described [25]. Aliquots of the
sample containing tryptic peptides were directly analyzed by MALDI-
TOF/MS for peptide mass ﬁngerprinting (PMF) analysis [26]. Peptide
mass lists, obtained after deisotoping, were submitted to UniProtKB
2010_11 (12898884 sequences; 4176319342 residues) using the MAS-
COT peptide mass ﬁngerprint program (version 2.2.07, Matrix Science,
UK). The main search parameters were: taxonomy: Homo sapiens; one
missed cleavage allowed; carbamidomethylation of cysteine as ﬁxed
modiﬁcation; oxidation of methionine as variable modiﬁcation; mass
tolerance of 50 ppm. Alternatively, tryptic peptides were analyzed by
nLC-ESI-MS/MS as already reported [27], generating amino acid se-
quence information too for protein identiﬁcation. All MS/MS samples
were analyzed using MASCOT engine to search the UniProtKB
2010_11 (12898884 sequences; 4176319342 residues).We used a pep-
tide mass tolerance of 200 ppm and 0.3 Da for precursor and fragment
ions, respectively. Searches were performed with trypsin speciﬁcity, al-
kylation of cysteine by carbamidomethylation as ﬁxed modiﬁcation,
and oxidation of methionine as variable modiﬁcation.
2.2.4.5. Western blot analysis. 40 μg total cellular proteins were sepa-
rated on SDS-10% polyacrylamide gel. Resolved proteins were elec-
trotransferred onto Hybond-ECL nitrocellulose membrane with an
ECL Semidry Blotter TE 77 PWR apparatus (GE Healthcare) for 1 h
at 0.8 mA/cm2 in transfer buffer (25 mM trizma base, 40 mM glycine,
20%methanol, 0.05% SDS). Membranes were probed for Lamin A/C, Trio-
sephosphate isomerase, Alpha B Crystallin, Actin and Alpha-Tubulin. De-
tection was by enhanced chemiluminescence (ECL) reaction (ECL
detection kit, GE Healthcare) and proteins were visualized on autoradi-
ography ﬁlms (Hyperﬁlm ECL, GE Healthcare). Densitometry values
were determined using ImageJ 1.45e software.
2.2.5. Bioinformatic analysis
2.2.5.1. Heatmap building. The heatmapwas generated by Stanford soft-
ware Heatmap builder version 1.0 freely available to the academic com-
munity (http://ashleylab.stanford.edu/tools_scripts.html). Heatmap is
presented as row normalized (maximum and minimum values are cal-
culated for each spot) ink-blot [28].
2.2.5.2. BiNGO (Biological Networks Gene Ontology). The proteins iden-
tiﬁed in this study were analyzed according to the three organizing
principles of Gene Ontology (GO: http://www.geneontology.org: BP:
Biological Process, MF: Molecular Function, CC: Cellular Component),
using the bioinformatic tool BiNGO v. 2.44, as a plug-in of Cytoscape v.
2.8 [29]. BiNGO is an open-source Java tool to determine which GO
terms are signiﬁcantly over-represented in a test set of proteins. We
used gene ontology.obo v.1.2 as reference set, GOSlim generic asontology ﬁle, a p-value threshold of 0.05 and Homo sapiens taxonomy.
Hypergeometric test with Benjamini and Hochberg correction for FDR
was applied. Indeed, we could determine not only the frequency of
each category for ours and reference set but also the ratio of these two
values, thus obtaining an indication of over-represented GO categories
in our proteins. Moreover, as regard theMF ontology, BiNGO permitted
us to build a graph where over-represented children categories are
reported as nodes. The area of each node is proportional to the number
of proteins in the test set annotated to the corresponding GO category.
Color code of the nodes indicates the statistical signiﬁcance.
2.2.5.3. Principal Component Analysis. Data were analyzed using Princi-
pal Component Analysis (PCA), a multivariate projection method des-
ignated to extract and highlight the systematic variation into a
multivariate data matrix. The method allows to investigate the original
data using a smallest number of variables (the principal components),
while preserving the greatest possible amount of information [30]. As
a consequence, data can be represented in a bi- tri-dimensional plot
which makes easy to visualize similarities, clusters or trend in the origi-
nal data.
The data matrix was constituted from N rows (19 biological samples,
including 18 LMNA mutation carriers versus all the neuromuscular dis-
ease controls collapsed in one) andK columns (73 spots). Before the anal-
ysis, since the large difference in the variables' numerical range, datawere
scaled to unit variance and mean-centered; in addition some variables,
which were markedly skewed, were log transformed. The analysis was
carried out using Simca-P 8.0 (Umetrics AB, Umeå, Sweden) software.
3. Results
3.1. Patient clinical and genetic characterization
Our cohort included 18 LMNAmutation carriers (Table 1). Thirteen
of these were initially referred to our center for neurological disease,
including limb-girdle (LGMD-1B) or Emery–Dreifuss (EDMD) muscu-
lar dystrophies and peripheral neuropathy, while ﬁve asymptomatic
LMNA mutation carriers were identiﬁed during family studies.
LMNAmutations comprised sevenmissense substitutions, one frame-
shift and one in-frame deletion and one splice donor site alteration. In
addition, two silent substitutions not leading to amino acid change
were included. Their presence in the normal population was excluded
by analysis of 180 healthy chromosomes. Variants were scattered along
the entire Lamin A/C protein, including head, coiled coil, Ig fold and tail
domains (Table 1).
Careful cardiological evaluation revealed in many cases a concom-
itant cardiac phenotype, characterized by dilated cardiomyopathy
(DCM), ventricular and supraventricular arrhythmias and conduction
defects.
To investigate pathways involved in the pathogenesis of Lamin A/C-
related neuromuscular disorders, we undertook a pilot protein proﬁling
study. Control groups included 12 patients affected by myopathy or
muscular dystrophy not related to LMNA mutations (neuromuscular
disease controls) and 3 unaffected subjects (healthy controls).
Among neuromuscular disease controls, one was affected by Becker
muscular dystrophy, three by limb-girdle muscular dystrophy, one
Bethlem and one desmin myopathy, two distal myopathies, three
metabolic myopathies and one peripheral neuropathy.
3.2. Protein proﬁling of human skin ﬁbroblasts from LMNA patients versus
healthy controls
In order to identify differentially expressed proteins in LMNA mu-
tation carriers (N=18) versus healthy subjects (N=3), skin biopsies
were performed and ﬁbroblasts were isolated as described in the
Methods section. Fibroblast lysates were separated using 2D
Table 1
Clinical and genetic characterization of LMNAmutation carriers. Year of birth for each patient is reported. LMNAmutations at DNA and protein level are described. Both neurological
and cardiac phenotypes are depicted.
Patient # Year of birth LMNA mutation (DNA) LMNA mutation (protein) Domain Neurological phenotype Cardiac phenotype
L-206 1979 c.31delC p.R11AfsX83 Head LGMD, TC VEB, SVEB
L-1224 1951 c.99G>C p.E33D Head LGMD, TC DCM, AF
L-218 1988 c.99G>C p.E33D Head Asymptomatic Asymptomatic
L-214 1982 c.99G>C p.E33D Head Asymptomatic INITIAL ARVD
L-216 1951 c.194A>G p.E65G Coil 1A LGMD, TC AVB, AF
L-227 1979 c.194A>G p.E65G Coil 1A LGMD, TC INITIAL ARVD
L-232 1960 c.471G>A p.T157T Coil 1B LGMD, TC ?
L-234 1959 c.565C>T p.R189W Coil 1B LGMD, PN DCM
L-222 1977 c.1039G>A p.E347K Coil 2B Asymptomatic INITIAL ARVD
L-235 1955 c.1380+1G>A Splicing alteration Ig fold LGMD, TC DCM
L-219 1975 c.1357C>T p.R453W Ig fold LGMD, TC AF
L-204 1961 c.1368_70delCAA p.N456del Ig fold LGMD, TC DCM, AF
L-203 1989 c.1368_70delCAA p.N456del Ig fold EDMD Asymptomatic
L-208 1955 c.T1535>C p.L512P Ig fold LGMD, TC AVB, NSVT
L-230 1984 c.T1535>C p.L512P Ig fold Asymptomatic Asymptomatic
L-190 1983 c.1683G>C p.L561L Tail PLD, PN ?
L-237 1949 c.1711C>T p.R571C Tail Asymptomatic INITIAL ARVD
L-236 1989 c.1711C>T p.R571C Tail EDMD, PN Asymptomatic
Legend: AF atrial ﬁbrillation; ARVD arrhythmogenic right ventricular dysplasia; AVB atrio-ventricular block; DCM dilated cardiomyopathy; EDMD Emery–Dreifuss muscular dystrophy;
LGMD limb-girdlemuscular dystrophy;NSVT nonsustained ventricular tachycardia; PLD partial lipodystrophy; PNperipheral neuropathy; SVEB supraventricular ectopic beats; TC tendon
contractures; VEB ventricular ectopic beats.
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(panel a) and LMNA patient ﬁbroblasts (panel b) are reported in
Fig. 1. Each sample was run in triplicate in order to obtain a statistical-
ly signiﬁcant image analysis of the spot intensities. We were able to
retrieve a total of 539 spots (data not shown) and we decided to de-
ﬁne as differentially displayed spots those with a fold-change thresh-
old≥1.5 and a p-valueb0.05. In order to be sure that we were looking
at relevant proteins, we focused our attention on proteins whose ex-
pression resulted to be concordantly changed in at least two patients.
This criterion permitted us to reduce the number of differential spots
up to 66, which were digested and analyzed by mass spectrometry.
Protein identities, pI, MW, sequence coverage, number of matched
peptides/measured peptides or fragmented peptides and Mascot
scores are reported in Additional ﬁle A.
Forty-eight unique proteins were grouped according to Gene On-
tology (GO) terminology, using the bioinformatic tool BiNGO. A
graphical description of the over-represented GO terms in our test
set of proteins is given in Additional ﬁle B (p-valueb0.05). In the
graph, protein categories are displayed according to their decreasing
statistical signiﬁcance. We found an enrichment of altered proteins
involved in metabolic processes, including carbohydrate metabolic
process and generation of precursormetabolites and energy (Additional
ﬁle B, panel a). The same graph illustrates an over-representation of
structural/cytoskeletal proteins. Indeed,when deeply analyzing themo-
lecular function ontology, we established protein binding category as
predominantly represented. Proteins assigned to this category were in-
volved in cytoskeletal protein binding and, more speciﬁcally, in actin
binding (Additional ﬁle B, panel b). This ﬁndingwas not surprising, con-
sidering that we were looking for proteins altered in cells derived from
patients affected by neuromuscular diseases; however, we could not
conclude whether the observed effects on protein expressionwere spe-
ciﬁcally related to LMNA defects or were a general consequence of neu-
romuscular disease.3.3. Protein proﬁling of human skin ﬁbroblasts from LMNAmutation carriers
versus neuromuscular disease controls
In order to understand whether our list of differentially expressed
proteins represented a speciﬁc effect of LMNA mutations or a general
phenotype of neuromuscular diseases, we subsequently compared
protein proﬁles of skin ﬁbroblasts from LMNA patients to those onesderived from other myopathies as controls. Representative 2D gels
of neuromuscular disease control ﬁbroblasts (panel a) and LMNA pa-
tient ﬁbroblasts (panel b) are reported in the Additional ﬁle C. Fig. 2
shows the heatmap in which the fold-changes (≥1.5 and p-
valueb0.05) for each spot and in each patient are reported. The iden-
tity of proteins, as revealed by mass spectrometry analyses, is also
listed (MS details are given in the Additional ﬁle D). Using the same
criteria reported above, we identiﬁed 47 unique proteins out of 73 an-
alyzed spots. As reported in Fig. 3, BiNGO analysis was very similar to
that obtained from the comparison of patients with healthy controls
(see Additional ﬁle B). Again, we could observe that the most affected
proteins were cytoskeletal/structural proteins and enzymes related to
carbohydrate metabolism. This data could suggest that the altered
protein expression was not a general consequence of the presence
of neuromuscular diseases, rather a speciﬁc effect of LMNA defects.
Moreover, a remarkable enrichment was observed for the oxidative
stress response activity (Fig. 3, panel a: ratio=17.61). This data was
further evident in the children graph (Fig. 3, panel b), where oxidore-
ductase activity was signiﬁcantly over-represented, according to the
color code for nodes.3.4. Clustering of LMNA patients according to their protein proﬁle
As reported in Table 1, our LMNA patients are characterized by dif-
ferent point mutations manifesting in a quite heterogeneous scenario
of clinical phenotypes. Nevertheless, we found that the same proteins
were differentially expressed in some patients. In order to deﬁne
which proteins, if any, could discriminate/cluster our patients, we
ran PCA on the data matrix containing the normalized spot volume,
as measured by SameSpots software, for the differentially expressed
proteins in each LMNA patient versus neuromuscular disease controls.
Results of the PCA (Fig. 4) showed that the ﬁrst and second compo-
nents respectively explained 24% and 17% of the variability of the
original data set, which was a quite good result for such complex bi-
ological samples. The score plot (Fig. 4, panel a) revealed a gathering
of some patients, for example: L-208 and L-206 (group 1); L-232, L-
230, and L-227 (group 2); and L-236, L-190, L-234, L-219 and L-235
(group 3). However, the control sample, which was composed by all
the neuromuscular disease controls, was scattered in the central
part of the graph close to other samples bearing LMNA mutations
(from now on, named scattered patients).
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Fig. 1. Representative 2D gels of human skin ﬁbroblast lysate. 300 μg total proteins were
loaded on 10% SDS–PAGE. The gels were stained with Colloidal Brilliant Blue Coomassie.
MW and pH range are indicated. Differentially displayed spots in LMNAmutation carriers
(panel b) versus healthy donors (panel a) are marked by numbers, as reported in the
Additional ﬁle A.
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plot, panel b), include: Lamin A/C (spots: 518, 649, 667), cytoskeletal/
structural proteins (Caldesmon, spots: 433, 434, 609, 611, 621; Alpha-
Actinin 1, spot: 474; PDZ and LIM domain 1, spot: 525; Septin 11,
spot: 1078; Alpha B Crystallin, spot: 2051) and proteins involved in
metabolic processes (Phosphoglycerate kinase 1, spot: 1286; Triose-
phosphate Isomerase, spot: 5213) (see Additional ﬁle D).
Due to the heterogeneity of LMNAmutation carriers (both at level of
mutation localization and clinical phenotype) and to the small number
of examined patients (however, we are analyzing a rare disease), no
clear gathering of patients was expected. Actually, we also tried to use
other variables to cluster our patients, but neither clinical phenotype,
nor disease onset nor point mutation localization in recognized lamin
domains gave rise to any reliable patient stratiﬁcation (data notshown). Therefore, our ﬁnding is indicating that, apart the above men-
tioned limits of this study, the protein proﬁling of ex-vivo cells is a
promising way to try to stratify patients.
3.5. Validation by semi-quantitative WB analysis
In order to uncover ﬁne differences among the groups, which
resulted from the PCA analysis, we further investigated three different
proteins byWB in a semi-quantitativeway: LaminA/C, Triosephosphate
Isomerase and Alpha B Crystallin. These proteins, not only were the
most relevant for patients' clustering (Fig. 4), but were also representa-
tive of themost altered protein categories as revealed by BiNGO results.
Skin ﬁbroblast lysates from two random patients in each group
and three random neuromuscular disease controls were analyzed in
triplicates by WB; protein content was normalized to Alpha-Tubulin
signal. Fig. 5 refers to a representative WB for the investigated proteins
and to the graphical box-plot representation of the densitometric ana-
lyses. Protein fold-changes, as obtained by comparing each group to neu-
romuscular disease controls, are reported. Overall, WB analysis not only
permitted us to validate our results, but also to highlight statistically sig-
niﬁcant differences among the recognized groups, suggesting that not a
single protein but, most likely, a panel of proteins might better cluster
our patients. In details, for Lamin A/Cwe found a p-valueb0.05 in all pair-
wise comparison between groups, except for Group 1 versus Group 3. As
regard Triosephosphate Isomerase, only the scattered patient group
resulted to be statistically different from the others; ﬁnally, Alpha B Crys-
tallinwas signiﬁcantly reduced in all the groups except forGroup3 (Fig. 5,
panels a, c and d, respectively).
It is noteworthy that Actin, initially used to normalize the amount of
protein loaded in the WB, was unexpectedly found to be not equally
abundant in our samples: indeed, it was signiﬁcantly decreased in
group 2 and scattered patients (Fig. 5, panel b). Even if unpredicted on
the basis of Progenesis SameSpots analysis, this result conﬁrms our
ﬁndings on the changes induced on cytoskeletal proteins. The discrep-
ancy between Progenesis SameSpots andWB analyses can be explained
considering themajor sensitivity of theWB that uses a speciﬁc antibody
directed against Actin.
4. Discussion
This work shows for the ﬁrst time the use of a proteomics ap-
proach to describe proteome-wide changes in LMNAmutation carrier
samples. So far, different cell culture models [31–33] or mouse
models [34] have been created to better understand the pathogenesis
of laminopathies, but here we present the ﬁrst proteomics data on pa-
tients. Findings of our study suggest that different pathways concur to
determine Lamin A/C neuromuscular diseases.
12 different LMNA mutations were included, scattered along the
entire protein sequence (Table 1) and thus not focusing on a particu-
lar molecular defect that could justify the disease. This cohort pre-
sented a heterogeneous scenario of clinical phenotypes from LGMD-
1B to EDMD muscular dystrophy, to dilated cardiomyopathy. Within
our cohort of patients, as also reported in literature [35], we observed
that the same LMNA mutation can cause diverse clinical phenotypes
(i.e. L-203 and L-204, Table 1), even including asymptomatic subjects
(i.e. L-218 and L-230, Table 1). Therefore, our hypothesis was that not
only lamin mutation but also other factors/proteins can explain the
disparate disease manifestations, which are not restricted to one tis-
sue/organ. Indeed, while not being the primary affected tissue, it
has been reported that nuclear alterations due to LMNA mutations
are also present in ﬁbroblasts from Emery–Dreifuss muscular dystro-
phy and familial partial lipodystrophy patients [36]. In addition,
mouse embryonic ﬁbroblasts lacking Lamin A/C, display a “fragile”
nucleus [37] and anomalies affecting cytoskeletal organization [38]
and, as also very recently shown, cytoskeleton-based cell functions
[39]. All together, these previous studies and the easier availability
8.4+8.5- 1 
Fig. 2. Heatmap of spots differentially displayed in human skin ﬁbroblasts from LMNAmutation carriers versus neuromuscular disease controls. The reported spots showed a fold-change
≥1.5 and a p-value b0.05. The color and size of dot indicates the different extent ofmore and less abundance. The larger size of the dot signiﬁes the greater discrepancy in expression level
between LMNA patients and neuromuscular disease controls. Identities of proteins are reported according to the mass spectrometry results (see Additional ﬁle D).
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Fig. 3. BiNGO analysis of human skin ﬁbroblasts from LMNAmutation carriers versus neuromuscular disease controls. Diagram refers to over-represented GO categories (as listed in
GOSlim generic) in our set of proteins, as compared to Homo sapiens proteome, using ontology.obo v.1.2 as reference set. The principal Y-axis refers to the frequency of each GO term
(x/X for our set or n/N for the reference set), while the secondary Y-axis refers to the ratio x/X/n/N (panel a). The graph reports the over-represented GO categories, which are
children of molecular function term (panel b). The color code for statistical signiﬁcance is indicated.
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pothesis that ﬁbroblasts may constitute a good candidate to evaluate
the effects of Lamin A/C mutations. We thus analyzed protein proﬁles
of skin ﬁbroblasts derived from patients and controls, to determine
speciﬁc alterations that could distinguish LMNA diseases from other
neuromuscular disorders. In the future, the extension of results
obtained fromﬁbroblasts tomuscular samples should permit to validate
our results.
Firstly, we identiﬁed a subset of differentially expressed proteins
in LMNA mutation carriers versus healthy controls (Additional ﬁle
A). However, since some proteins may be non-speciﬁcally linked to
disease progression, we subsequently compared protein proﬁles of
Lamin A/C patients with those of patients with other neuromuscular
disorders and no alteration in the LMNA gene (Additional ﬁle D).
We singled out commonly altered proteins, which could suggest the
affected biochemical pathways, even in distinct lamin mutation car-
riers. The list of identiﬁed proteins derived from the selection of sta-
tistically signiﬁcant changes (fold-change ≥1.5 and p-valueb0.05)
observed in at least two patients (Additional ﬁles A and D). We
adopted the criterion of two patients because, on one hand, we
wanted to balance the inter-individual variability, but on the other,
we knew that the mutations are distinct and rare, so that we could
not be too restrictive. Moreover, as discussed above, since the same
mutation can give rise to different clinical phenotypes, we could notexpect to ﬁnd so many common changes induced by different LMNA
mutations.
Upon comparison between LMNA patients and neuromuscular dis-
ease controls, we obtained 73 differentially displayed spots, corre-
sponding to 47 unique proteins. It has to be highlighted that the
number of spots is different from the number of the identiﬁed unique
proteins, as several spots are generated by the same protein likely
carrying different post-translational modiﬁcations, which can explain
the heterogeneity for each protein.
Among the others, we found that several spots related to Lamins A
and C were differentially expressed in our patients. These ﬁndings can
be ascribed to the effect of point mutations on the numerous post-
translational modiﬁcations, known to be present on lamins [40].
These results were also conﬁrmed when we compared the Lamin A/
C level in patients' groups by WB analysis (Fig. 5, panel a).
The unique proteins were deeply studied according to their GO
annotations, in order to delineate the altered pathways in our pa-
tients. BiNGO enrichment analysis (Fig. 3, panel a) suggested that
LMNA defects affect speciﬁcally the expression of proteins involved
in cytoskeleton organization, glucose metabolism and response to ox-
idative stress. Defects in structural support of nuclear architecture
caused by LMNA mutations had been previously suggested
[10,11,41]. According to this hypothesis, Lamin A/C defects may in-
crease nuclear fragility and reduce cytoplasmic elasticity, disrupting
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Fig. 4. Principal component analysis (PCA) of human skin ﬁbroblasts from LMNAmutation carriers versus neuromuscular disease controls. The score plot (panel a) shows the biological
samples into the space of the ﬁrst and second principal components, which account, respectively, for 24 and 17% of variability of the original data set. The loading plot (panel b) indicates
the spots distribution which determines the gathering of LMNA patients.
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provided by the LINC complex (LInker of Nucleoskeleton and Cyto-
skeleton) interacting with cytoskeletal networks. This may conse-
quently lead to a greater susceptibility to physical stress, especially
in tissues exposed to mechanical strain such as skeletal and cardiac
muscle. In addition, it has been recently proposed that Lamin A/C mu-
tations affect nuclear movement and positioning by impairing the an-
chorage of transmembrane actin-associated nuclear (TAN) lines
attaching the nucleus to actin cables [39]. In this study, we detected
differential expression of proteins involved in distinct cytoskeletal
networks: actin microﬁlaments (Caldesmon, F-actin-capping protein,
Gelsolin, Plastin 3, Tropomyosins, Zyxin); intermediate ﬁlaments
(Vimentin) and microtubules (Tubulin beta) (Additional ﬁle D). We in-
deed observed a clear reduced expression of some cytoskeletal/structural
proteins (Actinin alpha 1, Caldesmon, Plastin 3, Tropomyosins, and
Vimentin), thus conﬁrming the importance of cytoskeletal modiﬁcations
in Lamin A/C related neuromuscular disorders (Fig. 2).
Our cohort of patients also revealed signiﬁcant changes in the ex-
pression of proteins involved in cellular energy production. In many
patients, we found less abundant glycolytic enzymes (Phosphoglycerate
kinase 1, Triosephosphate Isomerase, Pyruvate kinase, Phosphoglycerate
mutase 1, L-lactate dehydrogenase B chain), consistent with a previous
report on HeLa cells with depleted expression of Lamin A/C [42]. Inthat study, the reduced (residual 9%) expression of lamins induced a de-
crease of metabolic enzymes (speciﬁcally, Triosephosphate Isomerase).
A recent work demonstrated alterations of glycolysis in a limb-girdle
muscular dystrophy patient showing down-regulation of glycolysis
genes, thus suggesting an intrinsic defect in skeletal muscle metabolism
due to Lamin A/C dysfunction [43].
Muscle oxidative stress has been proposed as a pathogenetic
mechanism for Duchenne muscular dystrophy, with dystrophin-
deﬁcient muscle cells clearly more susceptible to oxidative stress in
vitro [44]. In addition, recent ﬁndings show that free radicals play
an important role in cardiomyopathy inmdxmice. Fibrosis is a conse-
quence of oxidative stress in multiple tissues, including the heart [44].
Pathological modiﬁcations in free radical production in dystrophic mus-
cle could yield defects in regulatory systems that may underlie some of
the complex pathology of muscular dystrophy. Nevertheless, it is still
controversial whether oxidative damage is a signiﬁcant pathogenic
event inmuscular dystrophies, or it is a consequence. Our data suggested
an involvement of oxidative stress in the pathogenesis of Lamin A/C re-
lated muscular dystrophy and cardiomyopathy. In fact we found an al-
tered expression of Thioredoxin like protein 1, Thioredoxin reductase 1
and Peroxiredoxin 6, which are all proteins implicated in protection
against oxidative stress. Actually, an increased sensitivity to oxidative
stress in LMNA patients had been previously suggested [45,46].
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978 C. Magagnotti et al. / Biochimica et Biophysica Acta 1822 (2012) 970–979From our data, we can conclude that probably no single hypothe-
sis can explain the variability of phenotypes associated with Lamin A/
C defects and several molecular pathways likely concur to determine
the pathological phenotypes. From the PCA (Fig. 4), our patients
resulted to be divided into three major groups, considering both
structural and carbohydrate metabolic enzymes as the most relevant
proteins. This was evident in the loading plot (Fig. 4, panel b) and was
conﬁrmed by WB analysis (Fig. 5). Statistically signiﬁcant differences
were determined between any single group and the neuromuscular dis-
ease controls for each analyzed protein. Thus, in order to distinguish
among the groups, more than one altered protein/pathway has to be
considered.
A limitation of our study is related to the use of patient ﬁbroblasts.
Indeed, our results should be conﬁrmed on muscle biopsies which are
the target tissue of laminopathies. However, such a study on muscle
biopsy can introduce big issues concerning the heterogeneity of cell
types present in there.
As discussed above, the number of patients analyzed, which de-
pends on the rarity of the disease, was very small, impairing the pos-
sibility to draw deﬁnitive correlations between different phenotypes
and protein proﬁles. The limited number of patients was likely deter-
mining that no acceptable clustering was possible, considering other
variables, such as clinical phenotype, onset of disease or point muta-
tion localization in recognized lamin domains (data not shown).
In conclusion, we think that our study can contribute to better un-
derstand the molecular mechanisms of these rare diseases andeventually facilitate the deﬁnition of potential drug targets to develop
novel therapies.
Supplementary materials related to this article can be found online
at doi:10.1016/j.bbadis.2012.01.014.Acknowledgements
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